Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Rani Therapeutics Holdings (RANI) Change in Receivables (2020 - 2025)

Rani Therapeutics Holdings' Change in Receivables history spans 2 years, with the latest figure at $2.5 million for Q4 2025.

On a quarterly basis, Change in Receivables changed N/A to $2.5 million in Q4 2025 year-over-year; TTM through Mar 2026 was $1.4 million, a 140.33% increase, with the full-year FY2025 number at $2.0 million, changed N/A from a year prior.
Change in Receivables came in at $2.5 million for Q4 2025, up from -$1.0 million in the prior quarter.
The five-year high for Change in Receivables was $2.5 million in Q4 2025, with the low at -$1.0 million in Q2 2025.